Skip to content

S.M.B. TECHNOLOGY

Active
Public limited companyfounded 1987active for 39 yearsMarche, Rue du Parc Industriel 39, 6900 Marche-en-Famenne, BelgiumKBO/BCE: BE 0431.842.812
Summary

S.M.B. TECHNOLOGY has been active since 1987 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €19.6m and a net result of €2.5m. Equity remains stable across the filed financial years (±2.2% per year). Its solvency ranks better than 34% of 88 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21201
#3 employer in Marche-en-Famenne, Manufacturing sector1 site
Size
€94.5mturnover 2025
Staff
129 FTE
Equity
€19.6m
Profit
€2.5m
Financial health
93 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Largest shareholder
LABORATOIRES S.M.B. · 16%
Accounts 39 days early1 of 9 deeds read
Why 93raises risk1 of the last 3 latelowers riskFounded in 1987Size: turnover €94.5m, 129 FTE, total assets €56.8mLiquidity: current ratio 1.26, cash €10.3mShow the evidence

Checked score

Score 2025
93 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 42% of its sector peers (NACE 21)
Financial strength · tick = 2024
Average
Solvency 59+6
equity 34.4% of total assets
Liquidity 38-8
short-term debt 65.6% · cash 18.0%
Profitability 64-4
return on assets 4.4%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (26 companies, NACE 21, medium-sized)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.2%● unchanged vs 06-2025highest value 08-2025: < 0.1%▼ -0.2 percentage points vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026lowest value 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €1,800,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.26, compared with 1.18 in 2024; short-term debt: 65.6% and cash: 18% of total assets), and 65.6% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21): better than 32% on solvency, 37% on liquidity, 32% on profitability and 67% on growth.

The bankruptcy probability was computed on 08-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
lowers risk · Founded in 1987
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
lowers risk · Size: turnover €94.5m, 129 FTE, total assets €56.8m
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
lowers risk · Liquidity: current ratio 1.26, cash €10.3m
NBB · annual accounts
raises risk · 1 of the last 3 late
NBB · filings
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €19.6m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-06-2026, 39 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
39 days early
2024
13 days early
2023
58 days late
2022
3 days early
2021
114 days late
2020
125 days late
2019
194 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 62 days after the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (4 of the last 5 filed years within 62 days of that day).
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Capital & shares · MiscellaneousAmendment of the articles ·…
  3. Annual accounts filedfinancial year 2024 · full…

Key points

  • Positive: Employer in Marche-en-Famenne, Manufacturing sectorin the Checked rankings #3 View
  • Positive: 4 years of growth in a rowturnover 2025: €94.5m 4 years View
  • Caution: Result fell in 2025from €3.8m to €2.5m ▼ 34.4% View

By topic

Financials

Financial year
2025
Turnover
€94.5m
Profit
€2.5m
Solvency
34.4%
Turnover▲ 11.1%
Net result
20182025
Go to Financials

Timeline

Events
42
Since
1989
Next accounts
by 31-07-2027
  1. 31-12-2024Highest result from 2018 to 2025
  2. 27-09-2024Annual accounts filed
  3. 28-07-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
Founded
26-08-1987
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.